Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist plus anti-H2 receptor antagonist for treatment of refractory chronic idiopathic urticaria

References

• Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med. 2002;346:175–9
   PubMed Web of Science ®Google Scholar
• Grattan CE. The urticaria spectrum: recognition of clinical patterns can help management. Clin Exp Dermatol. 2004;29:217–21
   PubMed Web of Science ®Google Scholar
• Negro-Alvarez JM, Miralles-Lopez JC. Chronic idiopathic urticaria treatment. Allergol et Immmunopathol. 2001;29:129–32
   PubMedGoogle Scholar
• Goldsobel AB, Rohr AS, Siegel SC, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1986;78(5 Pt 1):867--73
   Google Scholar
• Zembowicz A, Mastalerz L, Setkowicz M. Safty of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol. 2003;139:1577–82
   PubMed Web of Science ®Google Scholar
• Goh CL, Tan KT. Chronic autoimmune urticaria: where we stand? Indian J Dermatol. 2009;54:269–74
   PubMedGoogle Scholar
• Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol. 2013;45:47--62
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64:1427–43
   PubMed Web of Science ®Google Scholar
• Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times convention al doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676–82
   PubMed Web of Science ®Google Scholar
• Monroe EW, Cohen Sh, Kalbfleisch J, et al. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol. 1981;117:404–7
   PubMed Web of Science ®Google Scholar
• Wan KS. Efficacy of leukotriene receptor antagonist with anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria. J Dermatolog Treat. 2009;20:194–7
   Web of Science ®Google Scholar
• Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA(2)LEN/EDF guideline: definition, classification and diagnosis of urticria. Allergy. 2006;61:316–20
   PubMed Web of Science ®Google Scholar
• Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37:631–50
   PubMed Web of Science ®Google Scholar
• Kozel MM, Mekkes JR, Bosuyt PM, et al. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45:387–91
   PubMed Web of Science ®Google Scholar
• Negro-Avarez JM, Carreno-Rojo A, Funes-Vera E, et al. Pharmacologic therapy for urticaria. Allergol Immunopathol. 1997;25:36–51
   Google Scholar
• Engstrom J, Neher JO, St Anna L. Clinical inquiry. What is the prognosis for patients with chronic urticaria? J Fam Pract. 2011;60:178a–b
   Google Scholar
• Maiti R, Jaida J, Raghavendra B, et al. Rupatadine and levocetirzine in chronic idiopathic urticaria: a comparative study of efficacy and safety. J Drugs Dermatol. 2011;10:1444–50
   PubMed Web of Science ®Google Scholar
• Mathias SD, Crosby RD, Zazzali JL, et al. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108:20–4
   PubMed Web of Science ®Google Scholar
• Brodell LA, Beck LA, Saini SS. Pathophysiology of chronic urticaria. Ann Allergy Asthma Immunol. 2008;100:291–7
   PubMed Web of Science ®Google Scholar
• Magen E, Mishal J. The effect of l-thyroxine treatment on chronic idiopathic urticaria and autoimmune thyroiditis. Int J Dermatol. 2012;51:94–7
   Google Scholar
• Soter NA, Lewis RA, Corey EJ, et al. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4) in human skin. J Invest Dermatol. 1983;80:115–9
   PubMed Web of Science ®Google Scholar
• Hani N, Hartmann K, Casper C, et al. Improvement of cold urticria by treatment with the leukotriene receptor antagonist montelukast [letter]. Acta Der, Venereol. 2000;80:229
   PubMed Web of Science ®Google Scholar
• Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy. 2000;55:203–4
   PubMed Web of Science ®Google Scholar
• Nettis E, Dambra P, D’Oronzio L, et al. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria [letter]. Arch Dermatol. 2001;137:99–100
   PubMedGoogle Scholar
• Ortonne JP. Urticaria and its subtypes: the role of second-generation antihistamine. Eur J Intern Med. 2012;23:26–30
   Google Scholar
• Beksuti DV. Second-generation antihistamines for the treatment of chronic idiopathic urticaria. J Drugs Dermatol. 2010;9:503–12
   Google Scholar
• Jauregui I, Ferrer M, Montoro J, et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007;17:41–52
   PubMedGoogle Scholar
• Kosnik M, Subic T. Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria. Respir Med. 2011;105:S84–8
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Chronic urticaria. Possible cause, suggested treatment alternatives. Postgrad Med. 1983;74:209–15, 218–22
   PubMed Web of Science ®Google Scholar
• Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012;16:1999–2005
   PubMed Web of Science ®Google Scholar